Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of formula (I):



(I)

wherein

R^2 is



wherein b is an integer of from 0 to 10;

R^3 is a C_{1-4} alkylene or C_{2-4} alkenylene bridge;

W_1 is absent or represents a spacer moiety which is a C_{1-30} hydrocarbyl group optionally including 1 to 10 heteroatoms selected from oxygen, nitrogen, and sulphur, and is

preferentially derived from glutaric and/or succinic acid and/or a polyethyleneglycol based unit and/or a unit of Formula :



Z_1 is an antineoplastic agent, a chelating agent or a reporter moiety.

2. (Original) A compound of formula (I) according to claim 1, wherein Z_1 is a reporter moiety comprising a radionuclide.

3. (Original) A compound of formula (Ia):



(Ia)

wherein

R^1 is either a bond or is



wherein a is an integer of from 1 to 30;

R^2 is



wherein b is an integer of from 0 to 10;

R^3 is a C_{1-4} alkylene or C_{2-4} alkenylene bridge;

the Linker is a C_{1-30} hydrocarbyl group optionally including 1 to 10 heteroatoms.

4. (Original) A compound of formula (Ia) according to claim 3 in which:
   R^3 is C_{1-4} alkylene;
   a is an integer of from 1 to 10; and
   b is 1.

5. (Previously presented) A compound of formula (Ia) according to claim 3 in which:
   R^3 is–CH_2-; and
   a is 5.

6. (Previously presented) A compound of formula (Ia) according to claim 3 in which the Linker is selected from (II), (III) and (IV) :

   $-(CH_2CH_2O)_n-(CH_2)_m-$ (II)

   $-(CH_2)_p-$ (III)



(IV)

wherein:

n is an integer of 1 to 20;

m is an integer of 1 to 10;

p is an integer of 1 to 20;

q is an integer of 0 to 4;

r is an integer of 1 to 10.

7. (Previously presented) A compound of formula (Ia) according to claim 3 which is:



8. (Previously presented) A compound of formula (I) according to claim 1 for use in medicine, particularly in the *in vivo* diagnosis or imaging, for example by PET, of a disease or condition associated with angiogenesis.

9. (Cancelled)

10. (Previously presented) A radiopharmaceutical formulation comprising a compound of formula (I) according to claim 1 and one or more pharmaceutically acceptable excipients.

11. (Original) A method of preparing a compound of formula (Ia) as defined in claim 3 which comprises reaction of the corresponding compound of formula (V):



(V)

wherein R^1, R^2, and R^3 are as defined for the compound of formula (Ia) and X is a leaving group selected from chloro, bromo, and iodo, and is preferably chloro;
by reaction with the appropriate compound of formula (VI):

$$^{18}F\text{-(Linker)-SH} \quad \text{(VI)}$$

wherein the Linker is as defined for the compound of formula (Ia).

12. (Original) A compound of formula (V) as defined in claim 11.

13. (Previously presented) A kit for the preparation of a radiofluorinated peptide of formula (Ia) according to claim 3 comprising:
(i) a compound of formula (VIa)

$$\text{L-(Linker) -SR} \qquad \text{(VIa)}$$

wherein L is a leaving group such as p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate,
the Linker is a $C_{1\text{-}30}$ hydrocarbyl group optionally including 1 to 10 heteroatoms;
R is hydrogen or a thiol protecting group;
and
(ii) an activated peptide of formula (V)



(V)

14. (Previously presented) A kit according to claim 13, comprising:

(i) a compound of formula (VIb), (VIc), or (VId):

$$L\text{-}(CH_2CH_2O)_n\text{-}(CH_2)_m\text{-}SR \quad (VIb)$$

$$L\text{-}(CH_2)_p\text{-}SR \quad (VIc)$$



(VId)

n is an integer of 1 to 20;

m is an integer of 1 to 10;

p is an integer of 1 to 20;

q is an integer of 0 to 4;

r is an integer of 1 to 10;

L is a leaving group such as p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate;

L' is a leaving group such as iodo, p-toluenesulphonate, trifluoromethanesulphonate, or methanesulphonate and when q is 0, L' can be nitro or an iodonium or ammonium salt,

R is hydrogen or a thiol protecting group; and

(ii) an activated peptide of formula (V)



(V)